Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Biocept presentation will be available on the Events & Presentation section of the Company’s website beginning Monday, September 11 at 7:00 a.m. Eastern time.
Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel.
Biocept is a molecular diagnostics company with commercialized assays for patients with solid tumors. Our experts have spent years working to improve the way physicians use cerebrospinal fluid for cancers that have spread to the central nervous system. Biocept has developed a unique, patented methodology to transport, isolate, and analyze cancer-derived materials from liquid specimens. As such, Biocept is a leading commercial provider of cerebrospinal fluid testing, enabling clinicians to rapidly detect cancerous involvement as well as identify and monitor therapeutic biomarkers.
Investor & Media Contact:
LHA Investor Relations
Jcain@lhai.com, (310) 691-7100